Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01263808 · ClinicalTrials.gov registry record · Phase 1
Cardiac Safety of Indacaterol
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 404
- Enrollment target
NCT01263808 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 404 participants.
The verdict
NCT01263808, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 404 participants
- Enrollment target
Study Summary
This study compares the cardiac safety of inhaled indacaterol with that of placebo and oral moxifloxacin.
Interventions
- DRUG Placebo
- DRUG Indacaterol 150 µg
- DRUG Indacaterol 300 µg
- DRUG Indacaterol 600 µg
- DRUG Placebo/moxifloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01263808
The ClinicalTrials.gov registry entry for NCT01263808 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 404 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01263808 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01263808 about?
NCT01263808 is a clinical study titled "Cardiac Safety of Indacaterol". This study compares the cardiac safety of inhaled indacaterol with that of placebo and oral moxifloxacin.
What is the current status of trial NCT01263808?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 404 participants. The study started on 2008-04.
What interventions are being tested in trial NCT01263808?
The interventions under investigation include: Placebo (DRUG), Indacaterol 150 µg (DRUG), Indacaterol 300 µg (DRUG), Indacaterol 600 µg (DRUG), Placebo/moxifloxacin (DRUG).
Who is sponsoring clinical trial NCT01263808?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.